Clinical trials: TAS 102
Metastatic Colorectal Cancer
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Thalidomide has both anti-angiogenesis and antiemetic effects, and its combined use with TAS-102 may reduce the gastrointestinal reactions associated with TAS-102, while enhancing antitumor efficacy and reducing the side effects…
- Trial name
- NCT05266820
- Testing
- Thalidomide, TAS-102
- Where
- 6 sites in China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma
iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This study will evaluate the safety and feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102) and Oxaliplatin (iTTo) for treatment naïve advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT04808791
- Testing
- Irinotecan, Oxaliplatin, TAS 102 (Trifluridine/Tipiracil)
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- AHS Cancer Control Alberta
Colorectal Cancer
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
- Trial name
- FRUITION (NCT06992258)
- Testing
- Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Criterium, Inc.
Metastatic Colon Cancer
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
This is a randomized phase II, open label, two arm study, evaluating the efficacy of panitumumab in combination with Trifluridine-Tipiracilas third line therapy, after a first line containing an anti-EGFR agent panitumumab(at…
- Trial name
- VELO (NCT05468892)
- Testing
- Trifluridine Tipiracil, Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
- Where
- 8 sites in Italy
- Volunteers
- 68 people
- Sponsor
- University of Campania Luigi Vanvitelli
Gastric Cancer
TAS-102 and Anlotinib in ≥3 Lines mGC
To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy
- Trial name
- NCT05029102
- Testing
- TAS 102, Anlotinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhejiang University
Pretreated Metastatic Colorectal Cancer
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study evaluating the safety and anti-tumor activity of TAS-102 administered in combination with Regorafenib in patients with metastatic…
- Trial name
- REMETY (NCT03305913)
- Testing
- TAS 102, Regorafenib
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- AIO-Studien-gGmbH
Colorectal Cancer, Metastasis
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
The purpose of this study is to compare progression free survival rates of metastasized colorectal cancer patients refractory or intolerant to systemic therapy with fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy and…
- Trial name
- SUNRISE-CRC (NCT03909724)
- Testing
- Sunitinib Malate, TAS 102
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Refractory Solid Tumors
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
The study is to explore the combination of nal-IRI and TAS-102, which is expected to be an effective regimen that could be applied to various cancers
- Trial name
- NCT03810742
- Testing
- Nanoliposomal Irinotecan
- Where
- 2 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- PharmaEngine
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Currently, the approved third-line treatments for metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil(TAS-102).
- Trial name
- NCT06403709
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Second-line Treatment of Metastatic Colorectal Cancer
The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin…
- Trial name
- BEV-TASIRI (NCT06242067)
- Testing
- Trifluridine/tipiracil
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Hospital of Shandong University
Gastric Cancer Adenocarcinoma Metastatic
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand.
- Trial name
- NCT06711471
- Testing
- trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- LIN YANG
mCRC
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
This single-center, single-arm, prospective study plans to enroll patients with advanced colorectal cancer who have failed first-line or higher systemic therapies.
- Trial name
- NCT07116577
- Testing
- Palliative radiotherapy, Iparomlimab and tuvonralimab, TAS-102
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Jinan Central Hospital
Previously Treated Metastatic Colorectal Cancer
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
This is a phase I/II study of the combination of Guadecitabine (SGI-110) and previously treated metastatic colorectal cancer patients. This study will be conducted in two components.
- Trial name
- NCT01896856
- Testing
- SGI-110 Dose Escalation, Regorafenib, TAS-102
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 118 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8
- Trial name
- NCT03992456
- Testing
- Panitumumab, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 18 sites in United States
- Volunteers
- 12 people
- Sponsor
- Academic and Community Cancer Research United